



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	227043	SB 500
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Spectrumceuticals Pty Ltd	
<b>Postal Address</b>	10/5 Narabang Way, BELROSE, NSW, 2085 Australia	
<b>ARTG Start Date</b>	19/08/2014	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . SB 500

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	2/06/2021
---------------------	-------------------------	-----------------------	-----------

#### Permitted Indications

Helps reduce occurrence of symptoms of traveller's diarrhoea  
Maintain/support intestinal health  
Maintain/support intestinal good/beneficial/friendly flora  
Maintain/support gastrointestinal system health

#### Indication Requirements

Label statement: Seek medical advice if diarrhoea persists for more than: 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3 to 6 years or 48 hours in adults and children over 6 years (or words to that effect).

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years, seek medical advice (or words to that effect).  
If symptoms persist consult your healthcare practitioner (or words to that effect).

#### Additional Product information

#### Pack Size/Poison information

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

#### Components

##### 1 . Formulation 1

<b>Dosage Form</b>	Capsule, hard
<b>Route of Administration</b>	Oral

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

**Visual Identification**

**Active Ingredients**

**Saccharomyces cerevisiae (Boulardii)** 500 mg

**Other Ingredients (Excipients)**

disodium edetate  
gellan gum  
hypromellose  
potable water  
potassium acetate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary